WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) announced that Shai N. Gozani, M.D., Ph.D., President and CEO, will participate in a panel titled “Roadmap to FDA Approval” on Tuesday, January 5 at the 2016 CES Event in Las Vegas. The panel moderator is Alfred Poor, Editor of Health Tech Insider. Dr. Gozani will be joined by other industry thought leaders including Dr. Nick van Terheyden, M.D., Chief Medical Officer at Dell, Bakul Patel, Associate Center Director for Digital Health at FDA, and Beth Bierman, Partner at Morgan Lewis & Bockius. The panel will address the opportunities and challenges of regulated wearable medical devices and apps. CES is the largest consumer technology event and has served as the launch pad for innovators and breakthrough technologies for almost 50 years. CES attracts global business leaders and pioneering thinkers to a forum where the industry’s most relevant issues are addressed.
“If wearable technology is going to achieve its tremendous potential it must move beyond wellness to tackling fundamental health problems such as chronic pain, diabetes, and heart disease. This necessarily implies regulation by the FDA,” said Dr. Gozani. “I hope this panel will start to demystify the regulatory process and encourage technology companies to embrace the opportunity of consumer medical technology. I believe that NeuroMetrix has some important experiences to share because of our 15 years as a traditional medical device company prior to transitioning into consumer health.”
CES attendees will have an opportunity to learn about Quell®, the NeuroMetrix wearable device for treating chronic pain. The Company will offer a first glimpse of the latest generation of Quell technology at Booth # 73313 in the Digital Health section of CES.
Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.
NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.